Skip to main content
    S

    Scinai Immunotherapeutics Ltd (SCNI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.40
    -0.04 (-9.50%)

    Market Cap: $1.05M

    Last updated: Nov 17, 2026 at 10:54 AM ET

    Scinai Immunotherapeutics Ltd (SCNI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Scinai Immunotherapeutics reported revenue of $1.31M for the fiscal year ended Dec 31, 2025, up 99.2% from the year before. That year, net income was -$8.31M with a net margin of -633.6%, operating cash flow was -$6.03M and free cash flow was -$6.05M. The quarter ended Sep 30, 2026 had revenue of $1.86M and net income of -$1.97M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.31M+99.2%-202.3%-575.3%-633.6%
    Dec 2024$658.00KN/A-88.1%-1312.8%728.9%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.31M$658.00K$0$0$0$0$0N/AN/AN/A
    Cost of revenue$3.96M$1.24M$512.67K$559.80K$747.65K$708.92K$461.69K$72.32K$123.55KN/A
    Gross profit-$2.65M-$580.00K-$512.67K-$559.80K-$747.65K-$708.92KN/AN/AN/AN/A
    Research and development$2.37M$5.53M$5.21M$5.76M$2.62M$14.42M$19.88M$19.27M$5.58M$2.44M
    Operating income-$7.54M-$8.64M-$9.71M-$11.06M-$10.79M-$19.82M-$22.69M-$20.61M-$6.80M-$3.09M
    Net income-$8.31M$4.80M-$6.50M-$5.80M-$12.38M-$1.30M-$31.62M-$23.46M-$9.93M-$2.38M
    EBITDA-$6.53M-$6.99M-$2.19M-$5.23M-$10.32M-$19.11M-$22.23M-$20.54M-$6.67M-$2.93M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.86M$467.90K$487.67K$263.64K$269.00K$386.50K$586.00K$206.00K$168.00K$284.00K$0$0
    Gross profit-$601.00K-$1.27M-$1.11M-$1.38M-$691.00K-$635.00K$228.00K-$167.00K-$249.00K-$164.00K-$157.73K-$84.91K
    Operating income-$1.95M-$2.18M-$2.46M-$2.82M-$1.89M-$1.88M-$1.57M-$2.26M-$2.42M$3.96M-$1.93M-$1.85M
    Net income-$1.97M-$2.04M$3.57M-$2.05M-$2.09M-$2.07M-$1.56M-$2.23M$10.46M-$2.32M-$2.16M-$2.36M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $623.00K by $1.04M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$11.63M$13.45M$17.47M$27.07M$32.04M$17.71M$33.52M$28.30M$23.48M$7.82M
    Current assets$2.05M$2.39M$5.45M$14.37M$17.84M$3.31M$21.17M$20.55M$21.64M$6.78M
    Cash and equivalents$1.66M$1.96M$4.87M$14.07M$17.37M$2.93M$20.98M$20.29M$20.51M$4.08M
    Total liabilities$3.52M$3.47M$22.04M$28.83M$31.05M$22.25M$52.36M$36.65M$7.31M$1.17M
    Short-term debt$329.00K$424.00K$396.00K$382.00K$623.36K$19.00M$200.97KN/AN/AN/A
    Long-term debt$294.00K$260.00K$19.37M$20.08M$63.25MN/A$123.78MN/AN/AN/A
    Shareholder equity$8.10M$9.98M-$4.57M-$1.76M$982.00K-$4.54M-$18.84M-$8.35M$16.17M$6.65M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$15.70M$17.17M$17.59M$11.63M$11.63M$11.84M$11.84M$13.45M$12.26M$14.85M$17.05M$17.47M
    Total liabilities$4.98M$5.44M$5.83M$3.52M$3.52M$3.98M$3.98M$3.47M$2.26M$22.14M$22.17M$22.04M
    Cash and equivalents$1.71M$2.85M$3.11M$1.66M$1.66M$989.00K$989.00K$1.96M$1.03M$3.08M$4.83M$4.87M
    Shareholder equity$10.71M$11.73M$11.76M$8.10M$8.10M$7.86M$7.86M$9.98M$10.00M-$7.28M-$5.12M-$4.57M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$6.03M-$6.33M-$9.38M-$7.26M-$7.43M-$21.09M-$22.31M-$15.29M-$2.89M-$2.51M
    Capital expenditures$24.00K$12.00K$637.00K$836.00K$139.00K$1.78M$2.15M$6.35M$1.30MN/A
    Free cash flow-$6.05M-$6.35M-$10.02M-$8.10M-$7.57M-$22.88M-$24.47M-$21.64M-$4.18MN/A
    Investing cash flow-$24.00K-$12.00K-$637.00K-$836.00K-$139.00K-$1.73M-$2.08M-$6.27M$1.94M-$2.03M
    Financing cash flow$5.77M$3.44M$1.09M$6.78M$21.43M$3.99M$24.68M$22.55M$17.77MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.88M-$2.50M-$1.45M-$1.73M-$1.53M-$1.04M-$1.08M-$2.04M-$1.75M-$1.46M-$1.23M-$2.22M
    Capital expenditures$115.00K$112.81K$3.00K$6.00K$3.00K$9.00K$0$4.00K$6.01K$2.00K$234.00K$20.00K
    Free cash flow-$1.99M-$2.61M-$1.46M-$1.73M-$1.54M-$1.05M-$1.08M-$2.04M-$1.76M-$1.47M-$1.46M-$2.24M
    Last 12 quarters

    Frequently Asked Questions About SCNI

    What is Scinai Immunotherapeutics' annual revenue?

    Scinai Immunotherapeutics reported revenue of $1.31M for the fiscal year ended Dec 31, 2025.

    How fast is Scinai Immunotherapeutics' revenue growing?

    Revenue was up 99.2% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Scinai Immunotherapeutics profitable?

    No. Scinai Immunotherapeutics reported net income of -$8.31M for the fiscal year ended Dec 31, 2025, with a net margin of -633.6%.

    How much free cash flow does SCNI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.03M minus capital expenditures of $24.00K produced free cash flow of -$6.05M.

    How much debt does Scinai Immunotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $294.00K, short-term debt of $329.00K and cash and equivalents of $1.66M.